ライフサイエンスコーパス: radioligand

1 ies and was selected for evaluation as a PET radioligand.

2 showed excellent kinetic properties as a PET radioligand.

3 the radioligand and (S,S)-68 displacing the radioligand.

4 ET with [(11)C]MePPEP, a CB1 inverse agonist radioligand.

5 wly developed dopamine transporter (DAT) PET radioligand.

6 uman tissues with (125)I-GLP-1(7-36)NH2 as a radioligand.

7 adioligand injection was virtually unchanged radioligand.

8 [(11)C]carfentanil, a selective MOR agonist radioligand.

9 the healthy volunteer white matter for both radioligands.

10 of either, inhibiting the development of PET radioligands.

11 gands; and sequential injection of different radioligands.

12 sitron emission tomography and TSPO-specific radioligands.

13 rospective clinical trials with several PSMA radioligands.

14 mor targeting are diagnostic and therapeutic radioligands.

15 rostate specific membrane antigen-617 (PSMA) radioligands.

16 y needed as versatile complementary tools to radioligands.

17 nthetic approach simplifies the discovery of radioligands.

18 visualized using translocator protein (TSPO) radioligands.

19 muSv/MBq, which is typical for (18)F-labeled radioligands.

20 crease the therapeutic index of the targeted radioligands.

21 ting MS patients were studied using the TSPO radioligand (11)C-(R)-PK11195.

22 positron emission tomography with the novel radioligand (11)C-dihydroergotamine, which is chemically

23 or radioligand (11)C-NNC 112, and the 5-HT2A radioligand (11)C-MDL 100907 at 6 and 9 mo of age.

24 or radioligand (11)C-NNC 112, and the 5-HT2A radioligand (11)C-MDL 100907 at 6 and 9 mo of age.

25 gand (18)F-MNI-659, the dopamine D1 receptor radioligand (11)C-NNC 112, and the 5-HT2A radioligand (1

26 gand (18)F-MNI-659, the dopamine D1 receptor radioligand (11)C-NNC 112, and the 5-HT2A radioligand (1

27 ls were imaged with the dopamine D2 receptor radioligand (11)C-raclopride, the PDE10A radioligand (18

28 ls were imaged with the dopamine D2 receptor radioligand (11)C-raclopride, the PDE10A radioligand (18

29 ing status, underwent PET scanning with TSPO radioligands ((11)C-PBR28 or (18)F-PBR111).

30 underwent a PET scan using the TSPO-specific radioligand [(11)C](R)-PK11195.

31 n emission tomography (PET) imaging with the radioligand [(11)C]AZ10419369 administered as a bolus fo

32 with positron emission tomography, using the radioligand [(11)C]AZ10419369 for quantification of cere

33 nteers using the mu-opioid receptor-specific radioligand [(11)C]carfentanil three times, as follows:

34 ssion tomography (PET) and the MOR-selective radioligand [(11)C]carfentanil.

35 ography (PET) scans with the 5-HT2AR agonist radioligand [(11)C]Cimbi-36: one at baseline and one or

36 mission tomography scans with the novel FAAH radioligand [(11)C]CURB and structural magnetic resonanc

37 d 16 healthy controls using PET and the TSPO radioligand [(11)C]PBR28.

38 n of activated microglia, as measured by the radioligand [(11)C]PK11195, and the regional distributio

39 orted CB2 positron emission tomography (PET) radioligand [(11)C]RSR-056, 38 fluorinated derivatives w

40 positron emission tomography (PET) with the radioligand [(11)C]SCH23390.

41 tron emission tomography (PET) with the SV2A radioligand [(11)C]UCB-J to examine synaptic density in

42 and sex-matched healthy controls, using the radioligands [(11)C]DASB (3-amino-4-(2-dimethylaminometh

43 utility of the novel 5-HT2A receptor agonist radioligand, [(11)C]CIMBI-36, and a d-amphetamine challe

44 Using a newly developed and validated radioligand, [(11)C]IMA107, the authors report the first

45 raphy scanning with the translocator protein radioligand 11C-PBR28 was performed at baseline.

46 ns of the positron emission tomography (PET) radioligand [11C]raclopride directly to subsecond dopami

47 the highly specific dopamine transporter PET radioligand, 11C-PE2I, to assess the association between

48 vivo kinetics of the novel tau-specific PET radioligand (18)F-AV-1451 in cognitively healthy control

49 ) was examined with the dopamine transporter radioligand (18)F-FE-PE2I (94 MBq) to evaluate the in vi

50 The novel radioligand (18)F-LY2459989 was synthesized by (18)F dis

51 d imaging characteristics of a novel tau PET radioligand (18)F-MK-6240 in humans.

52 tor radioligand (11)C-raclopride, the PDE10A radioligand (18)F-MNI-659, the dopamine D1 receptor radi

53 tor radioligand (11)C-raclopride, the PDE10A radioligand (18)F-MNI-659, the dopamine D1 receptor radi

54 efore, we recommend clinical transfer of the radioligand (18)F-PSMA-1007 for use as a diagnostic PET

55 The radioligand (18)F-PSMA-1007 was produced by a 2-step pro

56 f tau or TDP-43 pathology, indexed using the radioligand [(18)F]AV-1451.

57 dy uses the novel second-generation TSPO PET radioligand [(18)F]FEPPA to evaluate whether microglial

58 ith MS using the 18-kDa translocator protein radioligand [(18)F]PBR111.

59 Radioligands [(18)F]3b and [(18)F]3e were obtained in ac

60 e report the pharmacokinetics of a novel PET radioligand, (18)F-LSN3316612, which binds with high aff

61 for in vitro and in vivo characterization of radioligands(2), yet there exist few radiolabelling prot

62 n AD sections comparable to the tau-specific radioligand (3)H-T808; second, by very low nonspecific b

63 no group in 17 resulted in high affinity Y4R radioligands ([(3)H]-(2R,7R)-10, [(3)H]18) with subnanom

64 n determined in competition with the agonist radioligand [(3)H]7-hydroxy-N,N-dipropyl-2-aminotetralin

65 erties of tool compounds for CB2R (e.g., the radioligand [(3)H]CP55,940) are not optimal, despite the

66 etralin (7-OH-DPAT) than with the antagonist radioligand [(3)H]N-methylspiperone.

67 of the highly stable carbamoylguanidine-type radioligand [(3)H]UR-KAT479 ([(3)H]23), a subtype select

68 O and specific binding of two TSPO targeting radioligands (3H-PK11195 and 3H-PBR28) in tissue section

69 ntroduction of small-molecule PSMA inhibitor radioligands, 40 y after the clinical introduction of (1

70 The GRPR antagonist radioligands (67)Ga-, (111)In-, and (177)Lu-NeoBOMB1, in

71 with TCO (huA33-TCO) and a (67)Cu-labeled Tz radioligand ([(67)Cu]Cu-MeCOSar-Tz).

72 The PET radioligand (68)Ga-DO3A-VS-Tuna-2 ((68)Ga-Tuna-2) was de

73 e describe the characterization of an M1 PAM radioligand, 8-((1S,2S)-2-hydroxycyclohexyl)-5-((6-(meth

74 nge with unlabeled ligand failed to diminish radioligand accumulation in brain tissue, due to the blo

75 In addition, radioligand accumulation was seen in primary tumor lesio

76 ety data were obtained during and 24 h after radioligand administration.

77 The synthesis of such radioligands also needs to be very rapid owing to the sh

78 By using radioligand analysis, electrophysiology, and calcium ima

79 inding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand.

80 to those previously reported using the same radioligand and a high-resolution research tomograph.

81 These suggestions were checked by radioligand and electrophysiology experiments, which con

82 tive binding assays (IC(50)) and dual-tracer radioligand and fluorescence internalization studies.

83 ed using LNCaP cells and ((125)I-BA)KuE as a radioligand and reference standard.

84 egions of interest were the striatum for all radioligands and additionally the striatum, rostral cort

85 g 18-kDa translocator protein (TSPO)-binding radioligands and PET.

86 utility and the development of tools such as radioligands and positron emission tomography tracers th

87 ecular targets; coinjection of a cocktail of radioligands; and sequential injection of different radi

88 of neuroinflammation, most second-generation radioligands are sensitive to the single nucleotide poly

89 Three new radioligands based on BIBP3226, bearing an (18)F-fluoroe

90 We performed radioligand-based uptake studies at chimeric constructs

91 concern for therapeutic applications of PSMA radioligands, because therapeutic radiation will damage

92 0)Y-pentixather-a CXCR4-directed therapeutic radioligand-before conventional conditioning therapy fol

93 tistically significant reduction (-36.2%) in radioligand binding (HCs, 5.6; T1DMs, 3.6; P = 0.03).

94 adenosine receptor (AR) agonists) to enhance radioligand binding allosterically at the human dopamine

95 te resting-active-desensitized model to link radioligand binding and electrophysiological data.

96 ncerted transition model can be used to link radioligand binding and electrophysiological data.

97 binding configurations with a combination of radioligand binding and flux assays on wild-type and mut

98 e A1AR second extracellular loop (ECL2) with radioligand binding and functional interaction assays to

99 Methods: In vitro radioligand binding and internalization assays and cell-

100 uch that endoplasmic reticulum export of and radioligand binding and substrate uptake by these DAT mu

101 localization and quantitative correlation of radioligand binding and tau antibody staining on the sam

102 mutagenesis and the scintillation proximity radioligand binding assay improved our understanding of

103 The synthesized compounds were tested in radioligand binding assay on rat cortex against [(3)H]-c

104 e challenges (SPMChs) and PBMC B2AR numbers (radioligand binding assay) and signaling (cyclic AMP ELI

105 vestigated by Western blot analysis and by a radioligand binding assay.

106 ies rationalized the results obtained in the radioligand binding assay.

107 Radioligand binding assays first showed that they bind t

108 esized by organic chemistry and evaluated in radioligand binding assays using FAP-expressing HT-1080

109 ds: Synthesis, radiochemistry, stability and radioligand binding assays were performed for the novel

110 First, radioligand binding assays were performed to determine a

111 Radioligand binding assays were used to obtain structure

112 labeling, meeting the threshold required for radioligand binding assays.

113 s ligands of adenosine receptors, performing radioligand binding assays.

114 Readouts are radioligand binding competition, arrestin recruitment, a

115 Compounds were profiled using radioligand binding displacement assays, beta-arrestin r

116 nositol 1,4,5-trisphosphate accumulation and radioligand binding experiments to determine the impact

117 Through kinetic radioligand binding experiments, we characterized mutant

118 panel of receptors/channels/transporters in radioligand binding experiments.

119 R expression was maintained as determined by radioligand binding in LV sarcolemmal membranes.

120 overed substantial ubiquitous GSK-3-specific radioligand binding in Tg2576 Alzheimer's disease (AD),

121 Despite this, the influence of the radioligand binding kinetics on the kinetic parameters d

122 SSTR2 expression, and resulted in increased radioligand binding of (68)Ga-DOTATOC in NET cells.

123 TR2 expression in tumor cells, and increased radioligand binding of (68)Ga-DOTATOC to these tumor cel

124 Radioligand binding of compounds 11, 14, 15a, and 15c re

125 d a strong correlation was found between the radioligand binding signal for both tracers and the numb

126 Radioligand binding studies and functional assays that u

127 Radioligand binding studies show a significant age-relat

128 ist dissociation kinetics, and together with radioligand binding studies suggested a role for slow of

129 In radioligand binding studies, these compounds do not comp

130 ith negative cooperativity, demonstrated via radioligand binding studies.

131 by a combination of electrophysiological and radioligand binding studies.

132 ine was investigated using voltage-clamp and radioligand binding techniques.

133 void of tau pathology, excluding significant radioligand binding to any other central nervous system

134 Radioligand binding to brain homogenates revealed multip

135 scribe a novel method of kinetic analysis of radioligand binding to neuroreceptors in brain in vivo,

136 tion in brain tissue, due to the blocking of radioligand binding to plasma proteins that elevated the

137 2 adrenoceptors under condition of changing radioligand binding to plasma proteins.

138 Radioligand binding was blocked in a dose-dependent mann

139 TSPO radioligand binding was increased up to seven times for

140 g of only one radioligand was enhanced; SERT radioligand binding was minimally affected.

141 HxR (x: 1-4) subtypes on Sf9 cell membranes (radioligand binding, [(35)S]GTPgammaS, or GTPase assays)

142 amples and mode of action studies, including radioligand binding, inositol phosphate, and toxicity as

143 We performed muscarinic receptor radioligand binding.

144 5/7.18, comparable to binding constants from radioligand binding/flow cytometry; fast association/dis

145 Using radioligand-binding and functional assays, we posit that

146 nds have traditionally been characterized by radioligand-binding assays, which have low temporal and

147 based on systematic mutagenesis coupled to a radioligand-binding thermostability assay that can be ap

148 Compounds were characterized by radioligand competition binding and functional studies (

149 charge showed high M(2)R affinities (pK(i) (radioligand competition binding): 9.10-9.59).

150 lution, in vitro binding of the PD-sauvagine radioligand currently provides the most sensitive and ac

151 The resulting binding potentials of the radioligand declined by 50-60% in the presence of unlabe

152 First-in-human studies with PSMA radioligands derived from small-molecule PSMA inhibitors

153 n acceptable compromise between optimal PSMA radioligand design and a broad range of clinical demands

154 ctrophysiology in Xenopus laevis oocytes and radioligand displacement assays with human embryonic kid

155 These were evaluated in a radioligand displacement binding assay, a [(35)S]GTPgamm

156 e availability of cooperativity factors from radioligand displacement experiments are expected to imp

157 The new radioligands displayed Y(1)R affinities of 2.8 nM (12),

158 In [(3)H]N-methylscopolamine radioligand dissociation assays, approximately half of t

159 ly half of the 38 lead compounds altered the radioligand dissociation rate, a hallmark of allosteric

160 PET using ER- and PR-specific radioligands enables a whole-body, noninvasive assessmen

161 different receptor binding behavior of the 2 radioligand enantiomers.

162 The radioligand exhibited good in vivo stability and fast cl

163 nectin was labeled with (18)F to yield a PET radioligand for assessing PD-L1 expression in vivo.

164 18)F-PF-06684511 is the first successful PET radioligand for BACE1 brain imaging that demonstrates fa

165 hat [(18)F]8 is a promising PDE4B-preferring radioligand for clinical PET imaging.

166 [(18)F]RoSMA-18-d(6) is a promising CB2 PET radioligand for clinical translation.

167 luorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of alpha7-nA

168 s show that (18)F-LSN3316612 is an excellent radioligand for imaging and quantifying OGA in rhesus mo

169 udy is another step towards an optimized PET radioligand for imaging of Y(1)R in vivo.

170 e-NB1 is a highly selective and specific PET radioligand for imaging the GluN2B subunit of the NMDA r

171 F-tetrafluoroborate ((18)F-TFB), a novel PET radioligand for imaging the human sodium/iodide symporte

172 Conclusion: (18)F-MK-6240 is a promising PET radioligand for in vivo imaging of neurofibrillary tau a

173 lso scanned to assess the specificity of the radioligand for its target enzyme.

174 meno[3,4-f]-quinoline ((+/-)-(11)C-YJH08), a radioligand for PET that engages the ligand binding doma

175 (18)F-FET-betaAG-TOCA a promising candidate radioligand for staging and management of NETs.

176 ha]pyrimi dine-3-yl)acetamide (DPA-714) is a radioligand for the 18-kDa translocator protein.

177 mission tomography (PET) and [(11)C]UCB-J, a radioligand for the synaptic vesicle glycoprotein 2A (SV

178 that the future development of any improved radioligand for TSPO should consider the possibility tha

179 y (PET) with [(11)C]carfentanil, a selective radioligand for u-opioid receptors (uORs).

180 ical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

181 ical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

182 at (18)F-fluorodeprenyl-D2 is a suitable PET radioligand for visualization of MAO-B activity in the h

183 New radioligands for positron emission tomography have gener

184 The development of novel radioligands for specific immune-mechanisms is needed fo

185 The specificity of all 3 radioligands for tau aggregates was supported, first, by

186 idity of novel (18)F-GE-179 and (18)F-GE-194 radioligands for the detection of changes in active NMDA

187 using positron emission tomography (PET) and radioligands for the translocator protein (TSPO), a mark

188 the aim of this study was the development of radioligands for Y(1)R imaging by positron emission tomo

189 unlabeled ligand binding by the increase of radioligand free fractions in plasma.

190 Results: Each radioligand gave high early whole-brain uptake of radioa

191 incidence and mortality of PC, the new PSMA radioligands have already had a remarkable impact on the

192 c biomarker for ALS multicenter trials, TSPO radioligands have some challenges to overcome.

193 (11)C-JNJ-42491293, a novel high-affinity radioligand (human 50% inhibitory concentration = 9.6 nM

194 nt model and serial concentrations of parent radioligand in arterial plasma.

195 To detect any NR2B-specific binding of radioligand in brain, various preblocking or displacing

196 eins that elevated the free fractions of the radioligand in plasma.

197 ith the increase of the free fraction of the radioligand in plasma.

198 g (67/68)Ga-, (111)In-, and (177)Lu-NeoBOMB1 radioligands in GRPR-expressing cells and mouse models.

199 indicate that the high accumulation of PSMA radioligands in salivary glands does not correspond to h

200 of prostate-specific membrane antigen (PSMA) radioligands in salivary glands is still not well unders

201 e, that the significant accumulation of PSMA radioligands in SMG is not primarily a result of PSMA-me

202 e whether the accumulation of PSMA-targeting radioligands in submandibular glands (SMGs) can be expla

203 -11-labelled complex pharmaceuticals and PET radioligands, including a one-step radiosynthesis of the

204 rience over the last 3 years using different radioligands indicates that PRLT is highly effective for

205 For the other scan, a constant radioligand infusion was applied for 95 min, during whic

206 t radioactivity in rat brain at 30 min after radioligand injection was virtually unchanged radioligan

207 ron emission tomography with a D2R-selective radioligand insensitive to endogenous dopamine, (N-[(11)

208 ntravenous injection of one of the candidate radioligands into rats.

209 nsporters, and PET studies suggest that this radioligand is suitable for quantitative neuroimaging of

210 MAGL inhibitor 7 (PF-06809247) as a suitable radioligand lead, which upon radiolabeling was found to

211 nonspecific binding of the first-generation radioligand, low-resolution scanners, small sample sizes

212 hypothesized that imaging with EGFR-specific radioligands may facilitate noninvasive measurement of E

213 uced changes to agonist binding validated by radioligand measurements, and iii) testable hypotheses o

214 ing to correct for individual differences in radioligand metabolism.

215 breast cancer, targeting this receptor with radioligands might have a significant impact on staging

216 of general and efficient approaches to label radioligands necessary for drug discovery programs remai

217 tly employed histamine H(2) receptor (H(2)R) radioligands possess several drawbacks, for example, hig

218 tant-values was highly dependent on the used radioligand probe.

219 Positron emission tomography (PET) radioligands (radioactively labelled tracer compounds) a

220 [(3)H]6 constitutes the first GPR84 agonist radioligand representing a powerful tool for this poorly

221 Noninvasive PET/CT imaging using a CXCR4 radioligand revealed enlarged med-LNs with increased cel

222 The radioligand (S,S)-(11)C-2-(alpha-(2-methoxyphenoxy)benzy

223 Radioligands showed a rapid pharmacokinetic profile; how

224 c binding to Y(1)R in vitro and in vivo, the radioligands still need to be optimised to achieve highe

225 ort the suitability of (11)C-GSK1482160 as a radioligand targeting P2X7R, a biomarker of neuroinflamm

226 ort the suitability of (11)C-GSK1482160 as a radioligand targeting P2X7R, a biomarker of neuroinflamm

227 atic castration-resistant prostate cancer by radioligands targeting prostate-specific membrane antige

228 In recent years, several radioligands targeting prostate-specific membrane antige

229 PET radioligands targeting the 18-kDa translocator protein (

230 ssion tomography (PET) and [(11) C]ABP688, a radioligand that binds specifically to the mGluR5 allost

231 We used [(18)F]FPEB, a radioligand that binds to the mGluR5, and positron emiss

232 relationship study of a library of 25 novel radioligands that aims to identify radiotracers with opt

233 neuroimaging has been limited by the lack of radioligands that are selective for noradrenergic neurot

234 dvance in positron emission tomography (PET) radioligands that bind to the translocator protein (TSPO

235 ve been learned regarding the design of PSMA radioligands that have already been developed?

236 In comparison to other PSMA-targeting radioligands that have been evaluated in a PC3-PIP model

237 ely, a few notable successes in the targeted radioligand therapeutic space are changing this dynamic,

238 opportunity for a new and promising wave of radioligand therapies to significantly change the oncolo

239 rom 48 patients subjected to (177)Lu-labeled radioligand therapy ((177)Lu-DOTATOC, 26; (177)Lu-PSMA,

240 se were stratified to receive (90)Y-PSMA-617 radioligand therapy (mean, 3.2 GBq; range, 2.8-3.7 GBq);

241 te-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) using (177)Lu-labeled PSMA-61

242 d molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with (177)Lu-PSMA ligands.

243 te-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT), especially (177)Lu-PSMA-617.

244 e antigen (PSMA)-positive tumor volume after radioligand therapy (RLT) based on a pretherapeutic PET/

245 rostate-specific membrane antigen 617 (PSMA) radioligand therapy (RLT) in comparison with the establi

246 -motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT) in multiple myeloma and acute

247 Clinical (177)Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage p

248 Radioligand therapy (RLT) is considered a safe treatment

249 te-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is effective against prostate

250 617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic ca

251 Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a

252 might be used to overcome the limitations of radioligand therapy (RLT) with (177)Lu-prostate-specific

253 Radioligand therapy (RLT) with (177)Lu-PSMA-617 (PSMA is

254 Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA.

255 te-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT).

256 based PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current suc

257 However, PSMA-targeted radioligand therapy can cause undesirable effects due to

258 The use of (177)Lu-PSMA-based radioligand therapy has demonstrated a reasonable respon

259 ), making this antigen a suitable target for radioligand therapy of the disease.

260 ed prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands

261 Methods: Rechallenge radioligand therapy was defined as subsequent treatment

262 t (177)Lu prostate-specific membrane antigen radioligand therapy were retrospectively analyzed.

263 is an effective and promising candidate for radioligand therapy, with a favorable preliminary safety

264 ven the high level of safety of (177)Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 tox

265 s, low toxicity and improved QoL with LuPSMA radioligand therapy.

266 ate-specific membrane antigen ((177)Lu-PSMA) radioligand therapy.

267 f varying the beta-emitter in PSMA-targeting radioligand therapy.

268 promising target for diagnostic imaging and radioligand therapy.

269 etastatic castration-resistant PC after PSMA radioligand therapy.

270 d improved quality of life with (177)Lu-PSMA radioligand therapy.

271 is a highly promising candidate for targeted radioligand therapy.

272 r characterization, staging examinations, or radioligand therapy.

273 eceptor CB(2), in a Facade detergent enables radioligand thermostability assessments of this receptor

274 ding of a positron emission tomography (PET) radioligand to the vesicular monoamine transporter 2, (V

275 hy with the [(11)C]-(+)-PHNO and [(18)F]FPEB radioligands to quantify regional dopamine D(2/3) and me

276 opamine D(3) receptor-preferring agonist PET radioligand, to differentiate BCM in T1DM and HCs.

277 R agonist positron emission tomography (PET) radioligand, to investigate endogenous opioid tone in AD

278 TSPO radioligand uptake was increased in the brains of MS pat

279 nd (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 po

280 erocyclic positron emission tomography (PET) radioligands using the copper-mediated (18)F-fluorinatio

281 -bearing antibody and a tetrazine (Tz)-based radioligand via the rapid and bioorthogonal inverse elec

282 The radioligand was additionally used for labeling GPR84 in

283 The radioligand was characterized by kinetic, saturation, an

284 igands was enhanced; NET binding of only one radioligand was enhanced; SERT radioligand binding was m

285 Over 60% parent radioligand was present in plasma at 60 min.

286 modified with TCO, and a novel NOTA-PEG7-Tz radioligand was synthesized with the goal of improving o

287 , the binding of two structurally dissimilar radioligands was enhanced; NET binding of only one radio

288 Ex vivo brain autoradiography of radioligands was performed at subacute (5-6 d) and chron

289 n of (67)Ga-, (111)In-, and (177)Lu-NeoBOMB1 radioligands was studied in PC-3 cells at 37 degrees C,

290 The radioligands were characterized in vitro and in mice bea

291 sualized P2X7R in the monkey brain, and this radioligand will be further evaluated in a clinical sett

292 utetium-177 ((177)Lu)-PSMA-617 (LuPSMA) is a radioligand with high affinity for prostate specific mem

293 (177)Lu-PSMA-617 is a radioligand with high affinity for prostate-specific mem

294 son's disease using 11C-BU99008 PET, a novel radioligand with high specificity and selectivity for im

295 orts to develop a suitable (18)F-labeled PET radioligand with improved characteristics for imaging th

296 f neuroinflammation; and (ii) 18F-AV-1451, a radioligand with increased binding to pathologically aff

297 Whereas early studies using a radioligand with low signal-to-noise in small samples sh

298 or (H(1)R) antagonists were determined using radioligands with either slow (low k(off)) or fast (high

299 in vivo performance characteristics of both radioligands with the previously reported 3'-aza-2'-(18)

300 Thus, the new radioligand would likely have greater sensitivity in det